Whitehawk Q2 FY26 net loss narrows to $16.64 million
Reuters2026/08/06 12:06- Whitehawk Therapeutics posted a Q2 net loss of USD 16.6 million, narrowing from USD 52.6 million a year earlier.
- RD spending fell to USD 12.9 million from USD 48.8 million, on the prior-year quarter’s USD 38 million WuXi Biologics up-front license fee.
- Cash, cash equivalents and short-term investments rose to USD 190 million at June 30 from USD 145.7 million at Dec. 31, 2025.
- Phase 1 trials for HWK-007 and HWK-016 continued enrolling; HWK-206 Phase 1 initiation remains on track for Q3 2026.
- CEO Dave Lennon said the company extended its cash runway into 2H 2028 following an upsized financing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs: AI storage chip demand is underestimated, South Korean stock market still has 80% upside potential
Goldman Sachs Asia-Pacific Chief Equity Strategist Timothy Moe maintains a KOSPI target of 12,000 points, implying an almost 80% increase from the current level. He points out that the market is systematically underestimating the sustainability of the AI storage chip profit cycle. Capital expenditures by US tech giants may exceed $1.2 trillion next year, and the chip shortage triggered by data center expansion will further intensify in 2027. The current KOSPI is trading at only 5.3 times expected earnings, about half of its historical average.
Norwegian sovereign wealth fund may cut $80 billion US Treasury holdings; high-rated mortgage securities expected to become new favorites
Norway's sovereign wealth fund, with a scale of $2.3 trillions, has recommended reducing government bond holdings and reallocating funds towards higher-yielding fixed income assets.
Barclays names Takeo Kamai head of high-touch sales trading, Japan
Crypto prices
More
